Charles Payne here.

Host of Making Money on Fox Business.

In a few days, my team is hosting our Power Of Options Masterclass.

I’ve taught this class to thousands of my readers, and if you’ve never attended, this is your chance.

If you’ve never traded options before or want to see how they can add layers of exponential growth to your portfolio—plan on joining us for this live event.

( Register Now )
(Event details will be on the next page)

Now, you already know options can be a valuable trading tool.

Lots of leverage… mostly cheap contracts… and you get to define the level of risk you're willing to take.

By all accounts—they're a better way to grow your money than just buying securities.

So why do most people who try options end up losing money?

Well… my guess?

Most folks have no clue how to truly harness their power!

I’m talking about…

Profiting even if the stock moves against your initial prediction by adjusting positions (rolling, adding legs to create spreads)
Selling covered calls repeatedly and eventually making your stock ownership "free" by collecting more in premiums than you paid for the shares
Getting paid to buy leading stocks at a discount
Making money when stocks do nothing by using iron-condors or strangles and profiting from a stock staying range-bound (most people think you need movement to make money)

There's a massive difference between understanding how options work and knowing what to do when real money is at risk.

I've been trading options for 40 years. Through multiple crashes. Through markets that moved so fast most traders froze. With real capital on the line every single time.

Thousands of my readers have LOVED this class…

And the returns in their portfolios are there to prove it.

If you’re someone who wants to accelerate your returns, create discounted and nearly “risk free” positions, and generate cash from your portfolio year round—I highly recommend signing up.

No charge for the training, but spots will go fast.

( Register Now )
(Event details will be on the next page)

Charles Payne

3 Stocks That Could Be Next to Announce a Stock Split

Reported by Chris Markoch. Originally Published: 3/15/2026.

Key Points

Stock splits often follow strong periods of growth and rising share prices.
KLA, Eli Lilly, and McKesson all trade near or above $900 per share, putting them on investors’ split watch lists.
Strong fundamentals and bullish analyst outlooks could keep these stocks climbing in 2026.
Special Report: Elon Musk already made me a "wealthy man"

Stock splits are actions taken by corporations to make their shares more affordable for a broader set of retail investors. These usually follow a period of significant growth and/or innovation.

What is it about stock splits that captures investors' imagination? After all, the intrinsic value of the company hasn't changed. Still, investor psychology is one of the most important factors that drives a stock's short-term performance. It can be hard for retail investors to consider buying a stock trading at $500, let alone $1,000.

Silver paying 20% dividend. Plus 68% share gains (Ad)

Silver Is Now a Growth AND Income Play

For decades, silver paid nothing. That just changed. One tiny ETF is delivering 20% annualized distributions plus 68% share appreciation in just 5 months.

Click here to learn more about this fund.

Investors with only small amounts to invest may find lower-priced shares more accessible because they can buy more of them. However, sometimes you get what you pay for: stocks with strong share-price growth typically have a strong fundamental story to back them up.

For example, Costco Wholesale Corp. (NASDAQ: COST) has been on many analysts' lists of companies that could potentially split its stock for years. As of this writing, COST stock trades for just over $1,000 per share. That's pricey, but the stock has delivered share-price growth of over 200% in the last five years. Investors who shied away at $500 missed that gain, which didn't include the company's dividend.

On the other hand, Walmart Inc. (NYSE: WMT) announced a stock split in January 2024. The stock hasn't missed a beat, climbing more than 45% in the last 12 months and over 175% in the last five years, not counting dividends.

The takeaway for investors is that quality matters. Owning companies with strong growth can make a stock split an additional benefit, not a gimmick to lure buyers. Here are three companies that could split their stock in 2026.

Semiconductor Leader KLA Approaches $1,400 Per Share

KLA (NASDAQ: KLAC) designs and manufactures equipment, software, and services used by chipmakers for process control and yield management applications. It's not surprising that KLAC stock has jumped more than 375% in the last five years, and over 100% in 2025.

Even as KLAC trades above $1,400 per share, it remains roughly 13% below its consensus price target of about $1,600. After a strong run as part of the artificial intelligence trade, a stock split could be timely.

That said, investors may have to wait. KLA hosted an Investor Day on March 12, where the company announced a $7 billion share repurchase program and a 21% increase to its dividend — its 17th consecutive annual increase.

A company can announce a stock split at any time, and KLA reports its Q3 earnings for fiscal 2026 on April 29. Given the recent announcements at Investor Day, the board may choose to wait. Still, with the share price above $1,400, investors will keep wondering when a split might come.

Eli Lilly's GLP-1 Leadership Keeps the Growth Story Strong

Eli Lilly & Co. (NYSE: LLY) isn't part of the technology sector, but the stock has been behaving like a growth tech name. LLY is up more than 350% in the last five years. However, like many "growthy" tech stocks, it has cooled a bit recently — up about 18% in 2025 and down roughly 9% through March 12.

LLY trades just under $1,000 as of this writing, and analysts' consensus price target implies roughly 25% upside. That outlook is supported by expectations for earnings growth of around 35% over the next 12 months.

But it's the reason behind the growth that fuels split speculation: Eli Lilly is the clear market leader in the GLP-1 weight-loss category. The company could widen that lead if the U.S. Food & Drug Administration approves its oral GLP-1 candidate in 2026.

That potential catalyst — and the fact shareholders recently received a 15.3% dividend increase announced in December 2025 — may prompt the company to take a measured, wait-and-see approach to any split announcement.

McKesson's Quiet Rally Pushes the Stock Near $1,000

McKesson Corp. (NYSE: MCK) is a leading medical distributor in the healthcare industry. McKesson delivers medicines and medical supplies to hospitals, pharmacies, and doctors' offices across the U.S., helping ensure patients receive the care they need.

MCK is up more than 400% over the last five years and about 47% in the past 12 months, including a roughly 15% gain in 2026 as of March 12.

In its most recent earnings report, management raised guidance for FY2026, forecasting 12% to 16% revenue growth and 17% to 19% growth in adjusted earnings per share — the latter well above analysts' projection of about 11% growth.

The MCK share price is above $900 and is approaching the top of its 52-week range. Unlike some other names on this list, McKesson is trading roughly in line with consensus price targets, but analyst sentiment remains broadly bullish with many targets above $1,000. That includes JPMorgan Chase & Co., which carries the highest target at $1,107.

Core Scientific's $10 Billion AI Shift Unlocks Triple-Digit Upside

Reported by Thomas Hughes. Originally Published: 3/4/2026.

Key Points

Core Scientific is well-positioned to execute its strategy and realize its growing, greater-than-$10 billion revenue backlog.
Analysts and institutional data reveal strong support and potential for robust upside.
Short sellers pose a threat, along with the potential short-covering rally or squeeze.
Special Report: Elon Musk already made me a "wealthy man"

Core Scientific’s (NASDAQ: CORZ) stock has struggled to gain traction in early 2026, but don’t be fooled. The company’s strategic shift from Bitcoin mining to AI mining is accelerating, positioning the company for robust, profitable growth. Revenue is forecast to exceed a 30% compound annual growth rate (CAGR) over the next five years, and the market appears to be underpricing that outlook.

Trading at roughly 35x earnings in early March, a sustained 30%+ CAGR would imply the stock could be trading at under 10x projected 2030 earnings — a valuation change that corresponds to a 100% to more than 200% potential stock price increase over that period. A 100% rise would bring the stock in line with broad-market averages for current-year earnings while assigning no premium for earnings quality.

Core Scientific Reveals Traction With Business Shift

Silver paying 20% dividend. Plus 68% share gains (Ad)

Silver Is Now a Growth AND Income Play

For decades, silver paid nothing. That just changed. One tiny ETF is delivering 20% annualized distributions plus 68% share appreciation in just 5 months.

Click here to learn more about this fund.

Core Scientific’s fiscal Q4 2025 results were a mixed bag: revenue contracted and missed consensus, but several other metrics offset that weakness. A key driver was the decline in Bitcoin-related revenue as the business transitions to supporting AI workloads.

Colocation services, underpinned by contracts with CoreWeave (NASDAQ: CRWV), grew more than 250% year-over-year and are expected to continue expanding rapidly over the next two to three years. Management plans to nearly double capacity by early next year and to keep expanding to meet demand.

Margin results were mixed, but the overall takeaway favored investors.

Notable improvements included a roughly 330% increase in gross profit and a return to net income from a prior loss.

The downside was negative adjusted EBITDA, reflecting rapid expansion and the reduction of Bitcoin operations; management expects this to be temporary. The company did not provide formal guidance but said it will continue ramping revenue and capacity while monetizing its Bitcoin assets.

The balance sheet carries some risk: the shareholder deficit widened in 2025. However, much of the spending and cash burn is tied to growth investments intended to capture rising demand. Core Scientific reports more than $10 billion in contracted revenue, an amount that—at current Q4 2025 income levels—represents many years of operations. If execution continues, those contracts should drive cash flow and margin improvement as the investment cycle moderates.

Analysts Affirm Core Scientific’s Double-Digit Upside Potential

Analysts responded to the report with mixed sentiment but no major changes. MarketBeat tracked three early revisions: one upgrade to Buy, one reaffirmed Buy, and one reduction in price target while maintaining an Overweight (Buy-equivalent) rating. Collectively, these moves support the Moderate Buy consensus. The consensus price target stands at $25, implying roughly 55% upside from early-2026 support levels.

Institutional trends indicate continued backing: institutions—public and private funds, hedge funds, and corporations—own about 99% of the stock and have been accumulating for six consecutive quarters.

Activity on a trailing-12-month basis shows approximately $2.50 bought for every $1 sold, with buying accelerating in the back half of 2025 and into early 2026. That pattern suggests a supportive floor under the shares and the potential for a rebound.

Price action has been subdued but constructive, appearing to build a support base. The stock is consolidating within a narrowing near-term range, around the midpoint of its historical range, with technical signs of support. A move toward the top of the historical range is possible, though a stronger catalyst may be needed to reach fresh highs. Despite the favorable outlook, short-sellers remain a risk and could cap gains in the $20 to $22 range.

Thank you for subscribing to TickerReport, where we work around-the-clock
to bring you the latest market-moving news.

This email communication is a paid sponsorship from Paradigm Direct, a third-party advertiser of TickerReport and MarketBeat.

Contact Us | Unsubscribe

© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 N Reid Pl., Suite 620, Sioux Falls, SD 57103-7078. United States of America..